Key word for drugmakers in 2012 is survival through innovation and R&D

Published: 2012-01-05 07:00:00

Updated: 2012-01-05 07:00:00

The country’s pharmaceutical companies face tough times ahead with the government’s plan to slash drug prices starting April, heaping strain on the generic-focused Korean industry.

Currently, Korean firms remain jittery over how to sustain generic drug manufacturing.

“Given that most Korean...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK